Hospital Exemptions for ATMPs can fill an unmet need for patients. However, varied implementation and unclear guidance can negatively impact sustainable patient access.
More alignment is needed to ensure that the Hospital Exemption Pathway is used to fill gaps where commercial ATMPs are lacking, for more sustainable and equal access to safe ATMPs.
Out with the old, in with the new. What worked for small molecules and MAbs is irrelevant. We co-hosted this webinar with Impatient to help the audience uncover strategic frameworks, tailored for ATMP access challenges.
Europe lags in ATMP adoption due to low profitability, R&D spending, and clinical challenges, requiring innovative pricing and reimbursement for early access.
We discuss how payers will adapt to the ATMPs Revolution ,effecting the pricing and reimbursement framework.
What are ATMPs, and why the buzz? Inbeeo hosted a webinar addressing their market impact, focusing on US and EU challenges with 60+ participants in the Q&A.
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?
